CIS
REGN icon

Capital International Sarl’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital International Sarl’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9M Buy
25,458
+856
+3% +$583K 0.22% 95
2026
Q1 		$19M Buy
24,602
+1,331
+6% +$1.02M 0.31% 81
2025
Q4 		$18M Sell
23,271
-23,521
-50% -$16M 0.29% 80
2025
Q3 		$26.3M Sell
46,792
-7,027
-13% -$3.97M 0.45% 60
2025
Q2 		$28.3M Sell
53,819
-16,315
-23% -$9.11M 0.54% 55
2025
Q1 		$44.5M Buy
70,134
+5,099
+8% +$3.51M 1.01% 26
2024
Q4 		$46.3M Buy
65,035
+10,846
+20% +$9.1M 1.07% 24
2024
Q3 		$57M Buy
54,189
+7,053
+15% +$7.85M 1.46% 15
2024
Q2 		$49.5M Buy
47,136
+6,718
+17% +$6.51M 1.51% 14
2024
Q1 		$38.9M Buy
40,418
+9,279
+30% +$8.82M 1.29% 15
2023
Q4 		$27.3M Buy
31,139
+3,071
+11% +$2.53M 1.02% 21
2023
Q3 		$23.1M Sell
28,068
-2,716
-9% -$2.13M 1.06% 21
2023
Q2 		$22.1M Buy
30,784
+3,148
+11% +$2.43M 0.99% 21
2023
Q1 		$22.7M Buy
27,636
+2,969
+12% +$2.24M 1.15% 18
2022
Q4 		$17.8M Buy
24,667
+2,815
+13% +$2.08M 1.25% 13
2022
Q3 		$15.1M Buy
21,852
+2,218
+11% +$1.4M 1.22% 15
2022
Q2 		$11.6M Buy
19,634
+1,601
+9% +$1.04M 0.93% 18
2022
Q1 		$12.6M Buy
18,033
+5,819
+48% +$3.68M 0.62% 43
2021
Q4 		$7.71M Buy
12,214
+9,748
+395% +$5.99M 0.37% 83
2021
Q3 		$1.49M Sell
2,466
-137
-5% -$85.1K 0.13% 150
2021
Q2 		$1.45M Sell
2,603
-5
-0.2% -$2.53K 0.13% 160
2021
Q1 		$1.23M Buy
2,608
+53
+2% +$25.8K 0.12% 159
2020
Q4 		$1.23M Buy
2,555
+292
+13% +$158K 0.13% 147
2020
Q3 		$1.27M Buy
2,263
+106
+5% +$64.3K 0.16% 128
2020
Q2 		$1.34M Buy
2,157
+611
+40% +$347K 0.18% 116
2020
Q1 		$755K Buy
+1,546
New +$638K 0.14% 131

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital International Sarl's REGN Position: Q2 2026 in Review

Capital International Sarl increased its Regeneron Pharmaceuticals (REGN) stake by 3.5% in Q2 2026, buying an estimated $583K and bringing the position to 25,458 shares worth $15.9M. The position accounts for 0.22% of the portfolio, ranked #95.

Capital International Sarl first reported a position in REGN in Q1 2020 and has held it in 26 quarters since. The position peaked at $57M in Q3 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capital International Sarl held 25,458 shares of Regeneron Pharmaceuticals worth $15.9M as of Q2 2026.
  • Capital International Sarl bought 856 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $583K.
  • Regeneron Pharmaceuticals made up 0.22% of Capital International Sarl's portfolio in Q2 2026, its #95 holding.
  • Capital International Sarl first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Capital International Sarl's Regeneron Pharmaceuticals position peaked at $57M in Q3 2024.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capital International Sarl's 13F filing for Q2 2026, filed 12 Aug 2026.